Abstract 1340
Background
Breast cancer accounts for 10 to 20 percent of the total cancer cost. The direct cost of cancer care are the health care expenses directly related to prevention and cancer treatment. The indirect cost, 2-3 times the direct cost include presenteeism, disability to work, absenteism and workers compensation. The aim of this study is to achieve a better understanding of the direct cost and the importance of the variables.
Methods
This retrospective descriptive study used the administrative data of AZ KLINA linked to the Cancer Registry of Belgium. The study comprised women diagnosed with breast cancer between July 2015 and December 2015. The direct health care costs were calculated for the diagnostic and treatment phase up to 365 days after diagnosis. The costs were grouped according to the different kinds of medical interventions. Regression analyses were performed for 3 dependent variables i.e. the patient contribution, the health insurance cost and the total cost. The type of room, age, chemotherapy, radiation therapy, antibody therapy, disease stage, number of hospital visits and right for increased reimbursement were independent variables.
Results
The study population included 107 patients. The total mean cost of the diagnostic phase was 817 €, divided into the personal contribution of 80 € and the health insurance cost of 737 €. The mean patient cost of the treatment phase was 1.712 €, for the health insurance 17.282 €. The regression analyses revealed the number of hospital visits was significantly associated with total cost, patient cost and health insurance cost. The patient cost was highly predictive by the choice of the room. The total cost of the diagnostic phase for 107 patients was 87.377 €. Imaging 32.742 € and pathology 32.895 € were most important, followed by pharmacy 9.641 € and consultation 6.598 €. In the treatment phase radiotherapy 436.247 €, antibody treatment with trastuzumab 326.961 € were most important, followed by chemotherapy 189.729 €, hospitalisation cost 153.026 €, pathology cost 144.239 €, and surgery cost 134.251 €.
Conclusions
In our study an estimation was given of all direct medical costs of breast cancer of the diagnostic and treatment phase. The results can inform hospital executives and policy makers to determine further strategic decisions for financing breast cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Antwerp.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1122 - Platelets from metastatic cancer patients have increased aggregation and activation
Presenter: Meera Chauhan
Session: Poster Display session 3
Resources:
Abstract
2671 - Luminal B breast cancer prognosis prediction by comprehensive analysis of Homeobox genes
Presenter: Ayako Nakashoji
Session: Poster Display session 3
Resources:
Abstract
2650 - Long non-coding RNA E2F4as promotes tumor progression and predicts patient prognosis in human ovarian cancer
Presenter: Sun-Ae Park
Session: Poster Display session 3
Resources:
Abstract
1462 - FGF19 promotes esophageal squamous cell carcinoma progression by inhibiting autophagy
Presenter: Lisha Ying
Session: Poster Display session 3
Resources:
Abstract
5787 - Proof of concept on the role of ex vivo lung cancer spheroids, cytokines expression and PBMCs profiling in monitoring disease history and response to treatments.
Presenter: Raimondo Di Liello
Session: Poster Display session 3
Resources:
Abstract
5253 - Circulating microRNAs related to DNA damage response as predictors of survival in metastatic non- small cell lung cancer patients treated with platinum-based chemotherapy
Presenter: Dimitris Mavroudis
Session: Poster Display session 3
Resources:
Abstract
5286 - Prognostic value of CTCs in advanced NSCLC patients treated with platinum-based chemotherapy
Presenter: Silvia Calabuig-Fariñas
Session: Poster Display session 3
Resources:
Abstract
5781 - Exosomes in NSCLC as a source of biomarkers
Presenter: Elena Duréndez
Session: Poster Display session 3
Resources:
Abstract
1447 - The role of Pim-1 in the development and progression of papillary thyroid carcinoma
Presenter: Xin Zhu
Session: Poster Display session 3
Resources:
Abstract
1323 - Development and Validation of a RNA-Seq Based Prognostic Signature in Neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster Display session 3
Resources:
Abstract